RE:RE:RE:RE:Dose escalation It's that and bypassing resistance. Presumably these patients are failing treatment because of resistance. If they get the drug inside the cell and it stays in the cell then the freed docetaxel will do it's thing in most cases.
jeffm34 wrote: TH1902 doesn't need to be transformative to be successful anyways. Even if it's only as effective as Docetaxel alone but has less risk of side effects like neutropenia, it will still be an attractive drug to use over current therapy.
qwerty22 wrote: The goal for thtx is to get on the list in the first place with an approval. And second to have as strong a profile as possible so doctors are reaching for that drug as often as possible and eventually as early as possible. I think cancer analysts are looking to fit the drug in the pre-existing treatment landscape in a practical way, they aren't looking for transformative statements.